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Objectives The purpose of this study was to systematically review and perform a meta-analysis of the ability of cardiac
computed tomography angiography (CCTA) to predict future cardiovascular events and death.
Background The diagnostic accuracy of CCTA is well reported. The prognostic value of CCTA has been described in several
studies, but many were underpowered. Pooling outcomes increases the power to predict rare events.
Methods We searched multiple databases for longitudinal studies of CCTA with at least 3 months follow-up of symptom-
atic patients with suspected coronary artery disease (CAD) reporting major adverse cardiovascular events
(MACE), consisting of death, myocardial infarction (MI), and revascularization. Annualized event rates were
pooled using a bivariate mixed-effects binomial regression model to calculate summary likelihood ratios and
receiver-operating characteristic curves.
Results Eighteen studies evaluated 9,592 patients with a median follow-up of 20 months. The pooled annualized event
rate for obstructive (any vessel with 50% luminal stenosis) versus normal CCTA was 8.8% versus 0.17% per
year for MACE (p  0.05) and 3.2% versus 0.15% for death or MI (p  0.05). The pooled negative likelihood ra-
tio for MACE after normal CCTA findings was 0.008 (95% confidence interval [CI]: 0.0004 to 0.17, p  0.001),
the positive likelihood ratio was 1.70 (95% CI: 1.42 to 2.02, p  0.001), sensitivity was 0.99 (95% CI: 0.93 to
1.00, p  0.001), and specificity was 0.41 (95% CI: 0.31 to 0.52, p  0.001). Stratifying by no CAD, nonobstruc-
tive CAD (worst stenosis 50%), or obstructive CAD, there were incrementally increasing adverse events.
Conclusions Adverse cardiovascular events among patients with normal findings on CCTA are rare. There are incrementally
increasing future MACE with increasing CAD by CCTA. (J Am Coll Cardiol 2011;57:1237–47) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.011Since the first report of the use of contrast-enhanced computed
tomography (CT) to obtain noninvasive coronary angiograms
in 1995 (1), cardiac computed tomography angiography
(CCTA) has evolved to become a highly accurate method in
the diagnosis of coronary artery disease (CAD), comparable
to conventional invasive coronary angiography (2). As a
result, modern CCTA has been rapidly adopted clinically
for the assessment of symptomatic patients with suspected
CAD. Currently, scientific guidelines exist for the appro-
priate use (3), performance (4), and interpretation (5) of
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2010; accepted October 4, 2010.CCTA. Despite the current widespread use of CCTA, its
prognostic ability is not well defined.
The prognostic value of coronary calcification by CT has
been well described (6), but the ability of CCTA to predict
future clinical outcomes is less well established. The prog-
nostic value of normal CCTA has been reported in several
studies, but with varying outcomes (7–30). Some of these
studies were not adequately powered to detect differences in
rates of clinical outcomes such as death, myocardial infarc-
tion (MI), and coronary revascularization. A systematic
review from 2008 reported on the diagnostic accuracy,
cost-effectiveness, and prognostic value of CCTA, but the
prognostic assessment was limited by only 3 papers having
been reported, 2 in abstract format, at the time of analysis
(2). Several subsequent studies have been published in the
interim. A recent CCTA expert consensus statement spon-
sored by the American College of Cardiology and 6 addi-
tional medical societies points to the need for continued
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nostic data after CCTA (31,32).
Therefore, we undertook a sys-
tematic review and meta-analysis
of the available published liter-
ature to investigate the prog-
nostic value of normal CCTA
for major adverse cardiovascular
events (MACE), death, MI, or
coronary revascularization.
Methods
Data sources. We searched
MEDLINE, Cochrane Database
of Systematic Reviews, American
College of Physicians Journal
Club, Database of Abstracts of
Reviews and Effects, Cochrane
Methodology Register, Health
Technology Assessment database,
National Health Service Eco-
nomic Evaluation Database, Embase, and the Cochrane Con-
trolled Trials Register for studies published from January 1,
1995 through March 9, 2010. We used the text words and
related Medical Subject Headings (MeSH) for cardiac, CT,
angiography, prognosis, death, myocardial infarction, and sur-
vival. There were no language restrictions. Search results were
limited to adults. References of reviewed articles were also
Figure 1 Literature Search Results
Eighteen studies met criteria for inclusion. CCTA  cardiac computed tomography
Abbreviations
and Acronyms
CAD  coronary artery
disease
CCTA  cardiac computed
tomography angiography
CI  confidence interval
CT  computed
tomography
EBCT  electron beam
computed tomography
LR  negative likelihood
ratio
LR  positive likelihood
ratio
MACE  major adverse
cardiovascular event(s)
MDCT  multidetector
computed tomography
MI  myocardial infarctionsearched for relevant titles. Our PubMed search query was
(computed tomography or CT) AND (prognosis OR death
OR mortality OR myocardial infarction OR survival) AND
(cardiac or coronary) AND angiography AND (Humans-
[Mesh] AND adult[MeSH] AND (“1995/01/01”[PDAT] :
“2010/03/09”[PDAT]). We executed and reported our find-
ings according to the Meta-Analysis of Observational Studies
in Epidemiology (MOOSE) and Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) state-
ments (33–35).
Study selection. Two investigators (1 physician and 1
physician/epidemiologist) independently conducted the lit-
erature search and extraction of relevant titles. The title and
abstract of potentially relevant studies and review articles
were screened for appropriateness before retrieval of the full
article, where relevant. We included diagnostic studies of
CCTA with at least 3 months of follow-up for symptomatic
patients with known or suspected CAD reporting MACE,
death, MI, and coronary revascularization. We included
retrospective and prospective observational studies. We
sought to evaluate CCTA in a population consistent with its
current appropriate use (patients with symptoms of sus-
pected CAD); therefore, we did not include studies of
patient populations characterized as asymptomatic screen-
ing, pre-operative risk stratification, or routine follow-up
coronary artery bypass grafts or percutaneous intervention.
We excluded diagnostic accuracy studies without clinical
outcomes.
raphy.angiog
RetCO
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tors (1 physician and 1 physician/epidemiologist) indepen-
dently abstracted data using a standardized form. We
extracted the following demographic data: author, year of
publication, design, follow-up duration, sample size,
type of CT scanner (electron beam computed tomography
[EBCT], 16-slice multidetector computed tomography
18 Studies Included in Meta-Analysis of CCTA PrognosisTable 1 18 Studies Included in Meta-Analysis of CCTA Prognos
First Author (Ref. #) Year Design
Population
Known or Suspected CAD
Gopal et al. (12) 2009 PCO Known or suspected
Ostrom et al. (18) 2008 RetCO Suspected
Min et al. (16) 2007 PCO Suspected
Noda et al. (17) 2008 PCO Suspected
Pundziute et al. (20) 2007 PCO Known or suspected
Shaw et al. (21) 2008 PCO Suspected
Abidov et al. (29) 2009 PCO Suspected
Aldrovandi et al. (26) 2009 PCO Suspected
Barros et al. (27) 2009 RetCO Suspected
Cademartiri et al. (7) 2008 PCO Known or suspected
Carrigan et al. (8) 2009 RetCO Suspected
Chow et al. (24) 2010 PCO Suspected
Danciu et al. (28) 2007 PCO Suspected
Fazel et al. (10) 2009 RetCO Suspected
Gaemperli et al. (11) 2008 PCO Known or suspected
Hay et al. (30) 2009 RetCO Suspected
Rubinshtein et al. (19) 2006 RetCO Suspected
van Werkhoven et al. (22) 2009 PCO Suspected
SUM
Mean/median
CAD  coronary artery disease; Comp  comparison; Ou  outcome; PCO  prospective cohort;
Adverse Cardiovascular Events by Study and CCTA ResultTable 2 Adverse Cardiovascular Events by Study and CCTA Re
First Author (Ref. #)
No CAD
n MACE Death MI Revasc n
Gopal et al. (12) 157 0 0 0 0 204
Ostrom et al. (18) 1,085 18 18 1,060
Min et al. (16) 333 1 1 157
Noda et al. (17) 12 0 0 0 0
Pundziute et al. (20) 20 0 0 0 0 48
Shaw et al. (21) 303 1 1 39
Abidov et al. (29) 93 0 0 0 0 70
Aldrovandi et al. (26) 65 0 0 0 0 87
Barros et al. (27) 6 0 0 0 0 18
Cademartiri et al. (7) 23 0 0 0 49
Carrigan et al. (8) 96 0 0 0 0 76
Chow et al. (24) 591 0 0 0 866
Danciu et al. (28) 87 0 0 0 0 150
Fazel et al. (10) 376 0 0 0 0
Gaemperli et al. (11) 43 1 1 0 0 82
Hay et al. (30) 59 0 0 0 0 57
Rubinshtein et al. (19) 53 0 0 0 0 18
van Werkhoven et al. (22) 155 2 204
SUM 3,557 23 21 0 0 3,185
% Annual event rate 0.17 0.15 0.00 0.00CAD  coronary artery disease; MACE  major adverse cardiac event(s); MI  myocardial infarction; Re[MDCT] angiography, 64-slice MDCT angiography), age,
known or suspected CAD, and percentage of male sex.
Clinical outcomes included the raw data for the combined
outcome of MACE (all-cause mortality, nonfatal MI,
revascularization, and re-admission for unstable angina) and
the independent outcomes of all-cause mortality, cardiovas-
cular mortality, nonfatal MI, and revascularization. When
anner n
Follow-Up
(Months)
Age
(yrs)
%
Male
Quality
Sel/Comp/Ou–Total
EBCT 454 40 58 70 4/2/3–9
EBCT 2,538 78 59 70 4/2/3–9
6-slice 1,127 15 62 43 4/2/3–9
6-slice 30 10 65 43 3/0/1–4
6-slice 100 13 59 73 3/2/3–8
6-slice 693 16 62 52 4/2/3–9
4-slice 199 28 54 54 4/2/3–9
4-slice 187 24 63 64 4/2/3–9
4-slice 31 21 58 70 3/0/3–6
4-slice 98 20 67 32 3/2/3–8
4-slice 227 28 54 61 4/2/3–9
4-slice 2,076 17 58 52 4/2/3–9
4-slice 421 15 64 63 3/0/3–6
4-slice 436 36 55 45 4/0/3–7
4-slice 220 14 63 65 3/2/3–8
4-slice 138 20 57 73 3/0/3–9
4-slice 100 12 56 57 4/2/3–9
4-slice 517 22 59 59 3/2/3–8
9,592 429
224 20 59 58 8
 retrospective cohort; Sel  selection.
onobstructive CAD Obstructive CAD
CE Death MI Revasc n MACE Death MI Revasc
0 0 0 93 40 0 20 20
36 393 32 32
9 637 28 28
32 20
1 351 21 21
0 0 3 36 15 0 0 15
1 0 3 35 17 0 3 13
1 0 0 7 4 0 0 4
0 26 6 0 3
0 1 1 55 16 1 2 13
8 5 619 35 17 18
0 0 1 184 55 1 1 53
2 1 3 95 56 1 2 55
0 0 0 22 8 0 0 8
0 0 3 29 18 0 0 18
158 10
58 7 14 2,772 381 101 49 199
41 0.74 0.30 1.25 8.84 2.22 2.12 24.82is
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decision was made by consensus of all authors.
Quality assessment. Two reviewers independently rated
study quality using the Newcastle-Ottawa Scale for the
assessment of quality of observational studies. This instru-
ment is recommended for use by the Cochrane Collabora-
tive Group for the assessment of quality of nonrandomized
studies (36). Assessment of quality is graded by the descrip-
tion of patient selection (4 criteria), study-control group
comparability (1 criterion), and outcome assessment. Based
on previous recommendations, studies meeting 5 criteria
were considered to be high quality (36).
Data synthesis. Raw data for dichotomous event outcomes
were converted to annualized event rates and then pooled
using a bivariate mixed-effects binomial regression model,
using the “metandi” module in Stata (version 11.0 Special
Edition, StataCorp, College Station, Texas) (37). This
model was used due to frequent zero cells that occurred
because most patients with normal CCTA findings do not
have cardiac events, and hard events were not common even
among patients with abnormal scans. We then calculated
summary sensitivity, specificity, likelihood ratios, diagnostic
odds ratios, a Fagan’s nomogram (38), and summary
receiver-operating characteristic curves. As a sensitivity
analysis to test the validity of annualized event rates, we also
evaluated the dataset using absolute events for the 2  2
table for each study in the same binomial regression model.
The primary outcome was the negative likelihood ratio
Figure 2 Annual Event Rates Stratified by Cardiac Computed T
Percentage of annualized event rates for combined major adverse cardiac events
stratified by cardiac computed tomography angiography diagnosis of no coronary a
(50% stenosis). All groups were significantly different by analysis of variance (p (LR) of MACE (death, MI, unstable angina, or revascu- mlarization) after normal findings on CCTA. Secondary
outcomes included LR of death, MI, and revasculariza-
tion in addition to the sensitivity of CCTA to diagnose
patients for the risk of these future events. Our design
focused on sensitivity and LR because these are the
clinical parameters of interest for CCTA, which is used to
rule out CAD in symptomatic at-risk patients. We evalu-
ated specificity and the positive likelihood ratio (LR),
although these values are of lesser clinical utility for CCTA,
which is not a confirmatory test of future clinical events.
Stratified analysis was performed to evaluate for influence of
the covariates age, sex, type of CT scanner, population
studied (known or suspected vs. suspected CAD), and study
quality. We defined a normal (or negative) CCTA study as
no, minimal, or no significant CAD as reported in each
paper. Nonobstructive CAD was defined as worst stenosis
(by coronary lumen diameter of any coronary artery) of
50% and obstructive CAD as 50% coronary lumen
diameter stenosis by CCTA of any coronary artery.
Methods to explore heterogeneity within systematic reviews
of diagnostic studies are less well established than for random-
ized trials (39). The metandi module allows for assessment of
heterogeneity through summary statistic variability and graph-
ically with Galbraith plots (36). Additionally, we conducted a
sensitivity analysis of all summary estimates using a fixed-
effects model with calculation of the I2 statistic. The I2 statistic
rovides an estimate of the amount of variance due to heter-
geneity rather than chance and is based on the traditional
raphy Angiography Result
), death (all-cause), myocardial infarction (MI), and revascularization (Revasc),
isease (CAD), nonobstructive CAD (50% stenosis), and obstructive CAD
).omog
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March 8, 2011:1237–47 Prognostic Value of CCTAgeneity is significant, stratified analyses are conducted to assess
for potential confounders’ contribution to heterogeneity, in-
cluding age, sex, type of scanner, follow-up duration, quality of
study, clinical outcomes reported, and population studied
(known or suspected vs. suspected CAD). To exclude the
possibility that any one study was exerting excessive influence
on the results, we conducted a sensitivity analysis by system-
atically excluding each study at a time and then rerunning the
analysis to assess the change in effect size. Publication bias was
assessed using the method of Deeks et al. (40). This method is
preferred over conventional tests more commonly used for
randomized trial meta-analyses because these tests of publica-
tion bias or small study effects are less reliable for diagnostic
studies (40). The meta-analysis was performed with Stata
(version 11.0, StataCorp). To compare the mean annualized
event rates among the 3 CCTA outcomes (no CAD, nonob-
structive CAD, and obstructive CAD), analysis of variance was
performed using SPSS software (version 13.0, SPSS Inc.,
Figure 3 HSROC Curve for Prediction
of Future MACE by CCTA
Hierarchical summary receiver-operating characteristic (HSROC) curve for the
diagnostic performance of cardiac computed tomography angiography to dis-
criminate those with no coronary artery disease (CAD) from those with any evi-
dence of CAD for the prediction of combined major adverse cardiac events,
including all-cause mortality, myocardial infarction, and revascularization. The
size of the circles indicates the weight of each study. AUC  area under the
curve; Sens  sensitivity; Spec  specificity.Chicago, Illinois). Outliers were defined during sensitivity sanalysis as individual outcomes 2 SDs from the pooled
utcome. All p values were 2-tailed and with an alpha of 0.05.
esults
iterature search. The initial search yielded 2,254 refer-
nces. We eliminated 2,215 after initial screening. The
bstract or full text of the 39 remaining studies were
valuated to determine eligibility. Twenty-one studies
14,15,23,25,28,41–56) were excluded after further review
or reasons outlined in Figure 1. Eighteen studies were
dentified for inclusion from the literature search
7,8,10 –12,16 –22,24,26 –30). No additional studies were
dentified from the references of these articles. Two
uthors were contacted for additional information. Both
uthors replied; however, the studies lacked data on
ormal CAD outcomes and were excluded (42,57).
haracteristics of the included studies. Table 1 presents
he demographic data for the 18 included studies. There
ere 9,592 patients (6,035 positive CCTA findings and
,557 normal CCTA findings) included with a median
ollow-up of 20 months. The mean age was 59  2 years,
nd the patients were 58  10% male (range 32% to 73%).
ll studies followed a cohort of patients with symptoms
uspected to be attributable to CAD, evaluated with
CTA. Fourteen studies excluded patients with previously
iagnosed CAD (suspected CAD only). Four of the studies
ncluded patients with known CAD who were undergoing
ew evaluation for possible ischemic chest pain symptoms.
ne study was rated low quality, and the other 17 of the
ncluded studies were rated good quality (Table 1). Raters
greed 100% on categorical study quality (poor vs. accept-
ble, kappa  1.00). There was 95% per-point agreement
n each item per study of the Newcastle-Ottawa Scale
overall kappa  0.77, p  0.001).
nnualized event rates. Table 2 presents the clinical
utcomes by study and CCTA findings. MACE occurred
t an absolute rate in 0.6% of patients with negative scans
nd death or MI in 0.6% (all events were due to all-cause
ortality). There were no coronary revascularizations,
Is, or admissions to the hospital for unstable angina
mong those with normal findings on CCTA. Cardio-
ascular mortality was not able to be specified in most
apers because the method of assessing mortality was
ost often by the Social Security Death Index
16,21,22,24). Chow et al. (24) noted that the 1 death in
heir no CAD group was malignancy related. MACE
ccurred in 8.2% of patients with positive scans, and
eath or MI occurred in 3.7%. The weighted average
nnualized MACE rate for positive versus negative
CTA findings was 8.8% (predominantly revasculariza-
ion) versus 0.17% per year (p  0.05). For death or MI,
he weighted average annualized event rate was 3.2%
ersus 0.15% (p  0.05) for positive versus negative
cans. After stratifying by no CAD, nonobstructive
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Prognostic Value of CCTA March 8, 2011:1237–47CAD, and obstructive CAD, incrementally increasing
event rates were noted, as depicted in Figure 2.
Test parameters and likelihood ratios. Figure 3 depicts by
ummary of the receiver-operating characteristic curve the
est parameters for performance of CCTA to predict future
ACE among those with any CAD versus those without
ny CAD by CCTA. Figure 4 demonstrates the pooled
ensitivity and specificity for MACE by any CAD versus
o CAD. The specificity was heterogeneous in all sub-
roups. Figure 5 summarizes the likelihood ratios for
CTA diagnosis of no CAD versus nonobstructive CAD
ersus obstructive CAD, stratified by MACE, death, and
eath or MI. The pooled LR for MACE in patients
ith negative findings on CCTA was 0.008 (95% confi-
ence interval [CI]: 0.003 to 0.21, p 0.001, I2 0%);LR
.70 (95% CI: 1.42 to 2.02, p  0.001, I2  87%), sensitivity
.99 (95% CI: 0.93 to 1.00, p  0.001, I2  0%), and
pecificity 0.41 (95% CI: 0.31 to 0.52, p  0.001, I2  72%).
Figure 6 depicts how a LR and LR affect post-test
robability after CCTA for a hypothetical patient with a 20%
re-test probability of having future MACE.
ensitivity analysis. There was no significant heterogene-
ty by I2 for MACE, death, MI, or revascularization when
omparing the LR by any of the outcomes among the
ubgroups any CAD versus no CAD and no CAD versus
Figure 4 Pooled Sensitivity and Specificity for Future MACE Us
Sensitivity was homogeneous across this outcome and other subgroups. Specifici
CI  confidence interval; EBCT  electron beam computed tomography; MACE onobstructive CAD. Two outlier studies were identifiedor obstructive versus nonobstructive CAD by MACE (Min
t al. [16] and Ostrom et al. [18]) (Fig. 7). For this small
ubgroup, only these studies were excluded from the final
uantified analysis.
There was no evidence of publication bias by the Deeks et
l. (40) test (p  0.10). Stratified analysis showed that the
ffect size was not dependent on sex, patient population
suspected or known/suspected CAD), or quality of study.
uration of follow-up and type of scanner were significantly
elated to effect size. The sensitivity analysis demonstrated
hat 78% of the MACE in the no CAD group occurred in
he paper by Ostrom et al. (18). This paper was also an
utlier in terms of duration of follow-up (78 months).
owever, outcomes did not significantly differ after exclud-
ng the Ostrom et al. (18) study (LR  0.0099; 95% CI:
0.002 to 0.59; p  0.001). A comparison of the sensitivity
to rule out CAD associated with future adverse events by
type of scanner was underpowered due to the few studies in
each stratum. Evaluation of revascularization rates by scan-
ner type was underpowered because only 2 studies of
16-slice scanners and 1 EBCT angiography study reported
revascularization. For studies that used only 64-slice
MDCT, the sensitivity to predict MACE was 99.9% (95%
CI: 0.58 to 1.00; p  0.001). For those that used 16-slice
MDCT angiography or EBCT angiography, sensitivity to
Bivariate Mixed-Effects Binomial Regression Model
heterogeneous.
adverse cardiac event(s).ing a
ty was
majorpredict MACE was 98% (95% CI: 0.81 to 1.00; p 0.001).
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March 8, 2011:1237–47 Prognostic Value of CCTASensitivity analyses conducted to test the validity of
pooled annualized event rates compared the annualized
event rates to an analysis performed with absolute counts for
respective 2  2 tables. The latter method produced similar
effect sizes, but was limited by an inability to estimate a
logistic model for several subgroups and significant hetero-
geneity. For example, for the pooled MACE using absolute
rates for any CAD versus no CAD, theLR was 0.02 (95%
CI: 0.00 to 0.11; p  0.001; I2  81%), the LR was 1.70
(95% CI: 1.4 to 2.1; p  0.001, I2  95%), sensitivity was
0.99 (95% CI:, 0.96 to 1.00; p  0.001; I2  83%), and
pecificity was 0.41 (95% CI: 0.31 to 0.53; p  0.001; I2 
98%). Use of annualized event rates was more homogeneous.
Discussion
Although the diagnostic accuracy of CCTA has been
reported in 50 studies and meta-analyses (58,59), the
prognostic value of CCTA for predicting clinical events is
less defined. Our systematic review and meta-analysis is the
first comprehensive analysis of multiple recent longitudinal
studies describing the prognostic value of CCTA (7–25).
We have shown that the absence of CAD on CCTA
conveys an excellent prognosis for symptomatic patients
being evaluated for suspected CAD. The low annual event
rate for those with normal CCTA findings is comparable to
the background event rate among healthy low-risk individ-
uals (1%) (60). In addition, the low event rate for normal
findings on CCTA of 0.16% is comparable to the event rate
reported in a previous meta-analysis of patients with normal
findings on other noninvasive risk stratification modalities,
Figure 5 Pooled LR for Future MACE, Death, Death or MI, MI
Absolute event rates are displayed. Likelihood ratios were pooled by annualized ev
parameters and summary receiver-operating characteristic curves. There were no M
culated for those comparisons. *Two heterogeneous studies (Min et al. [16] and
abbreviations as in Figures 1, 2, and 4.such as stress echocardiography (0.45%) and myocardial per-
fusion scan (0.54%) (61). There were no definite CAD-specific
events in the group with normal CCTA findings (all 23 events
were all-cause mortality) over a median follow-up of 20 months
(maximum 78 months). As shown in Figures 3, 4, and 5, CCTA
has excellent sensitivity (99%) and LR (0.008) to exclude
future coronary clinical events when pooled across the 9,592
patients with symptoms of possible angina in these 17
studies over a median 20-month follow-up duration.
Where CCTA findings were abnormal, we found incre-
mentally increasing cardiovascular events (MI and revascu-
larization) and all-cause mortality rates with increasing
severity of CAD (Fig. 2). For patients with nonobstructive
disease, the event rates are higher than those without
disease. A marked increase in events (including death) is
seen for those with obstructive CAD (at least 1 lesion with
50% stenosis). The increase in events seen between groups
stratified by CAD severity was also consistent among each
of the components of the primary outcome variable
(MACE): death, MI, and coronary revascularization.
Therefore, the concept that CCTA offers anatomic but not
prognostic value compared with widely used functional
stress testing is no longer accurate.
However, although adverse events are rare among pa-
tients with normal CCTA findings, a positive scan is not
strongly predictive of future MACE. This is because many
patients with CAD do not have events when followed over
20 months (the annualized MACE incidence was only
8.8%; thus, the majority of patients even with disease do not
have outcomes). Specificity and LR are less clinically
Revascularization Stratified by CCTA Findings
tes using a bivariate mixed-effects binomial regression model to calculate test
evascularization events in the no CAD group; therefore, no likelihood ratio is cal-
et al. [18]) removed from this end point. LR  negative likelihood ratio; other, and
ent ra
I or r
Ostrom
1244 Hulten et al. JACC Vol. 57, No. 10, 2011
Prognostic Value of CCTA March 8, 2011:1237–47meaningful when used in this setting, and we focused a
priori on LR and sensitivity because CCTA is a rule-out
test, as demonstrated in Figure 6. Furthermore, the speci-
ficity and LR are heterogeneous in this setting, although
this is expected because most meta-analyses of diagnostic
tests have at least 1 heterogeneous test parameter and the
specificity of CCTA for prediction of future MACE is
anticipated to vary by characteristics of the study population
such as age and pre-existing disease, although available
subgroups to analyze for these effects were small in this
meta-analysis.
There are several additional important considerations in
viewing this information. First, the authors of many of the
earlier studies included in this analysis reported prognosis
based on a relatively simple classification of CAD luminal
stenosis, specifically, no CAD, nonobstructive CAD, or
potentially obstructive CAD (50% stenosis). Although
Figure 6 Fagan’s Nomogram for Prediction
of Future MACE by CCTA
Fagan’s nomogram for the prediction of future major adverse cardiac events by
cardiac computed tomography angiography (CCTA) for a hypothetical patient
with a 20% pre-test probability of disease, comparing CCTA positive findings
(any coronary artery disease [CAD]) with CCTA negative findings (no CAD).
LR_Negative  negative likelihood ratio; LR_Positive  positive likelihood ratio;
Post_Prob_Neg  negative post-test probability; Post_Prob_Pos  positive
post-test probability.some studies defined normal findings on CCTA as theabsence of disease and some allowed for no or minimal
disease, this type of stratification has value and is informa-
tive clinically. For example, the presence or absence of
potentially obstructive CAD is typically the main clinical
question being sought by providers referring symptomatic
patients for CCTA. However, more precise measurements
of overall CAD burden, such as the number of vessels or
coronary segments involved or with stenosis, location (e.g.,
left main or proximal left anterior descending artery involve-
ment), number of vessels with severe stenosis (70%), and
potentially overall plaque volume or plaque scores have
been shown to provide refinement of patient prognosis
(16,21,24). In addition to lumen stenosis, other plaque
characteristics, such as individual plaque volume, the
presence and degree of coronary artery positive remodel-
ing (expansion), plaque calcification characteristics, and
the presence of very low density plaque, may also influ-
ence prognosis and require further study (13,15,62).
This analysis included studies using different generations
of CT scanning technology. For example, 2 studies were
included that used EBCT, and 4 were conducted with
16-slice MDCT scanners, a technology since surpassed by
even more modern (64-, 256-, and 320-slice and dual-
source) MDCT scanners, which have higher spatial resolu-
tion and overall improved image quality. The results dem-
onstrating a very good prognosis in the absence of CAD and
an incremental increase in annual MACE rates with in-
creasing degrees of coronary artery stenosis were consistent
when stratified by scanner type, although there is known to
be increasing angiographic accuracy with newer generations
of CCTA (63,64). However, this meta-analysis was not
powered to detect differences in prognostic value compara-
tively by each scanner subtype because there were only 2
studies using EBCT, 4 using 16-slice MDCT, and the
remainder using 64-slice MDCT. All scanner types had
good test parameters for ruling out future CAD outcomes
(Fig. 4). However, most events among patients with normal
CCTA findings (18 all-cause deaths) occurred in the
Ostrom et al. study with EBCT angiography, resulting in
decreased sensitivity (due to increased false negatives) for
that study of 0.84 (95% CI: 0.64 to 1.00) (Fig. 4).
Although our study was not limited by significant statis-
tical heterogeneity for almost all end points’ sensitivity and
LR (except for 2 outlier studies for the MACE outcome
for obstructive CAD vs. nonobstructive CAD), we evalu-
ated for trends among subgroups with stratified analyses and
metaregression in this subgroup. We also examined the
heterogeneity within the specificity and LR. However,
significant heterogeneity among at least 1 test parameter in
meta-analyses of diagnostic studies is a frequently reported
occurrence (65). Evaluation of heterogeneity for reviews of
diagnostic studies is less robust than for randomized studies,
but we used Galbraith plots to inspect for outliers and
influential studies, stratified analyses, and metaregression.
Stratified analyses showed no significant impact of baseline
sex, age, whether the study included patients with estab-
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variable (we annualized event rates to deal with differential
follow-up). Last, it is important to re-emphasize that this
analysis pooled studies of variable follow-up durations by
converting to annualized event rates. This method is limited
by its reliance on stable event rates, which is an imperfect
assumption, although often used in prognostic studies. We
evaluated for the effect of this assumption by performing
sensitivity analyses by absolute event rates in addition to
excluding studies with 12- or 24-month duration, but
the overall effect sizes were not significantly different and
were limited by greater heterogeneity. Of note, the overall
length of follow-up of a median 20 months is relatively
short. In the study with the longest follow-up duration by
Ostrom et al. (18), CCTA became less able to discriminate
events, suggesting that a “warranty period” exists on the
duration of noninvasive prognostic studies (66). Long-term
follow-up studies using 64-slice (or greater) MDCT are
currently not available.
Study limitations. The study is limited by verification
bias like many studies of noninvasive coronary risk
stratification tests (67). In the 17 included studies, it was
not always possible to separate coronary revascularization
performed for acute coronary events from that performed
for ongoing, chronic, stable chest pain referred for
follow-up angiography based on CCTA findings. Hence,
the observed increase in MACE is driven in part by
coronary revascularization, demonstrating evidence of a
workup or verification bias. That is, patients with CCTA
Figure 7 Graphical Assessment for Outliers for Sensitivity and
Two studies (Min et al. [16] and Ostrom et al. [18]) outlied for the end point of m
with cardiac computed tomography angiography showing nonobstructive coronary aevidence of a 50% stenosis are more likely to undergocatheterization and subsequent revascularization. This
has been shown with other noninvasive assessments of
CAD to decrease specificity, although the sensitivity may
be unchanged or spuriously elevated. Hard events (death
or MI) are less susceptible to verification bias and
remained significantly predicted by degree of CAD
seen on CCTA (Fig. 2), although the effect size and
statistical power was diminished without including
revascularization.
Despite the aforementioned limitations, our data clearly
demonstrate that normal CCTA findings convey a very low
risk of future death, MI, or coronary revascularization, at an
annual event rate comparable to an otherwise healthy
population. Furthermore, hard MACE and revasculariza-
tion increased with increasing CAD from no disease to
nonobstructive to severe disease. Considered in concert with
the wealth of data regarding the high anatomic accuracy for
CCTA (2), these results are convincing for CCTA to
effectively diagnose CAD and convey risk strata for future
adverse cardiovascular events.
Conclusions
Adverse cardiovascular events among patients with normal
CCTA findings are very rare and comparable to a baseline
risk among healthy patients. Increasing burden of CAD on
CCTA is associated with an increasing rate of revascular-
ization, MI, and death. However, for prediction of clinical
events, the specificity and LR are not useful for abnormal
ificity
verse cardiac events comparing patients
isease (CAD) with those showing obstructive CAD.Spec
ajor ad
rtery dCCTA findings (as expected and consistent with other
1246 Hulten et al. JACC Vol. 57, No. 10, 2011
Prognostic Value of CCTA March 8, 2011:1237–47noninvasive tests because many patients with disease will
not have clinical events and, as such, are “test positive
without events” in the context of this analysis). For predict-
ing prognosis of adverse clinical events, the LR of CCTA
with normal findings is comparable to reported values for
stress myocardial perfusion scan or stress echocardiography.
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